AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Fiercebiotech

Published November 12, 2026

ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veterans | Fierce Biotech

Read the full story at Fiercebiotech

psychedelic back in 2025. Agency leaders ... psychedelics —and larger reductions in PTSD both immediately and one month after treatment.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics
Ketamine